MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock
$5,047,606
Proceeds from the
exercise of warrants
$91
Net cash provided by
financing activities
$4,640,238
Canceled cashflow
$407,459
Change in cash, cash
equivalents and restricted...
-$8,254,201
Canceled cashflow
$4,640,238
Stockbased compensation
$478,141
Foreign currency loss
(gain)
-$95,319
Issuance of common stock
to consultants
$39,050
Depreciation and
amortization
$21,715
Common stock issuance
costs
$407,459
Net cash used in
operating activities
-$12,894,439
Canceled cashflow
$634,225
Net loss
-$12,599,569
Accounts payable
-$646,701
Prepaid expenses and
other current and...
$217,906
Accrued expenses
-$64,488
Back
Back
Cash Flow
source: myfinsight.com
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)